TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year~* Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months~* Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening~* Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening~Exclusion Criteria:~* Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening~* Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening~* Participants must not be taking certain diabetes medications that are not allowed for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY900014 + Insulin Degludec (Type: EXPERIMENTAL): LY900014 (100 units/milliliter (U/mL)) is a prandial insulin administered subcutaneously (SC) 0-2 minutes before meals. Insulin degludec (100 U/mL) is a basal insulin administered once daily SC. Participants received individually adjusted insulin doses during the 35-day titration period. The target glucose values were: fasting glucose 80-110 milligrams per deciliter (mg/dL), overnight glucose excursion (the difference between bedtime and prebreakfast glucose levels) \< or = +/- 30 mg/dL, postprandial glucose peak \<140 mg/dL or \<20% increase from premeal level. Following the titration period, there was an 11-day maintenance period during which the doses were kept unchanged unless for safety reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Manuka Eye Drops on Tear Film Properties

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;~* General population aged 18 years and over;~* In good general health;~* Subjectively experiencing dry eye symptoms (e.g. burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun). Participants will be selected based on a minimum OSDI score of 13 points (1).~* Willing to discontinue CL wear for 1 week before first visit and continue to do so until the conclusion of the study;~* Participant is willing to discontinue their use of any previous conventional dry eye treatment method commenced before the study throughout the study;~* Willing to comply with the dosage and study visit schedule as directed by the investigator;~* No planned changes to diet and willing not to substantially alter their usual diet for the duration of the study, including their typical intake of fish, green tea or oral supplements known to have anti-inflammatory properties;~* Willingness to notify the study investigator if instructed to alter their diet by health/medical practitioner.~Exclusion Criteria:~* Allergy to benzoic acid preservatives;~* Allergy to honey products;~* Active anterior eye disease/ infection, inflammation/allergy that requires ocular medical treatment;~* Eye injury or surgery in the past 6 months including chemical burns, penetrating injuries, traumatic iritis, orbital fractures, laser surgery, strabismus surgery, cataract or any other intraocular surgeries;~* Soft contact lens, rigid gas permeable, orthokeratology lens wearer within one week prior to the study and during the study.~* Use of any of the following medications (including steroids) up to 12 weeks prior to start of the study or during the course of the study:~  * Ocular medication, category S3 and above;~ * Any systemic or topical medications that will affect ocular physiology e.g. anti-acne medications such as Roaccutane and corticosteroid or immunosuppressant medications such as Hydrocortisone, Prednisolone and antihistamine medications such as Claritine;~* Any systemic disease that may affect ocular health e.g. Graves disease, and auto-immune diseases such as ankolysing spondylitis, multiple sclerosis and systemic lupus erythematosis;~* Epilepsy or history of migraines exacerbated by flashing, strobe-like lights.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Manuka eye drops (Type: EXPERIMENTAL): None
- Systane Ultra (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has histopathologically or cytologically confirmed diagnosis of stage 3 or 4 squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx.~2. The patient has local advanced, and no distant metastatic, and unresectable disease.~3. The patient has measurable or valuable disease. 4 Age ≥ 20 years.~5. ECOG performance status 0, 1 or 2 at study entry. 6. Life expectancy ≥ 3 months. 7. The patient must have adequate organ function, defined as: 7a Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L; Hemoglobin~* 9.0 g/dL. 7b Total Bilirubin ≤ 1.5 times upper limit of normal (ULN); Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN. 7c Alkaline phosphatase ≤ 2.5 x ULN. 7d Serum creatinine ≤ 1 x ULN or creatinine clearance ≥ 60 mL/min/1.73 m2. 8. Signed informed consent. 9 Women of child-bearing potential and men must be willing and able practice adequate contraception prior to study entry and for the duration of study treatment.~Exclusion Criteria:~1. The patient had previous chemotherapy or radiotherapy for squamous cell carcinoma of head and neck.~2. The patient has uncontrolled disorder(s), serious illness or medical condition(s) is/are not be enrolled to study that be confirmed by investigator.~3. Previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated and without evidence of recurrence for at least 3 years prior to the study.~4. Peripheral neuropathy \> Grade 2.~5. The patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- biweekly TPF induction (Type: EXPERIMENTAL): Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexamedetomidine for Interscalene Brachial Plexus Block on Plasma Biomarkers After Rotator Cuff Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. a definite rotator cuff tear that needed repair seen on preoperative magnetic resonance imaging~2. acceptance of arthroscopic surgery including rotator cuff repair~3. age more than 20 years,~4. acceptance of preemptive regional block , PCA and blood sampling after 1 ,6, 12, 24, 48 hour postoperatively. .~Exclusion Criteria:~1. they did not undergo arthroscopic rotator cuff repair~2. they stopped PCA before 48 hours postoperatively because of associated side effects~3. there was a history of a previous shoulder operation or fracture~4. there was a concomitant neurologic disorder around the shoulder~5. refusal of blood sampling.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- arm 1 (Type: ACTIVE_COMPARATOR): received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
- arm 2 (Type: PLACEBO_COMPARATOR): received ISB with 8mL of ropivacaine with 1ml of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed classical Hodgkin's lymphoma~  * No lymphocyte-predominant Hodgkin's lymphoma~ * Fine-needle biopsy not sufficient~* No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for a large mediastinal tumor~PATIENT CHARACTERISTICS:~* No known hypersensitivity or contraindication to study drugs~* No other current malignancy~* No severe concurrent disease (e.g., immune deficiency syndrome)~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment~* No known HIV positivity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy or radiotherapy~* At least 30 days since prior and no other concurrent investigational drugs or participation in another investigational trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- COPP (Type: ACTIVE_COMPARATOR): procarbazine-containing consolidation chemotherapy arm
- COPDAC (Type: EXPERIMENTAL): procarbazine-free consolidation chemotherapy arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease~Exclusion Criteria:~* known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before enrollment~* concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole)~* platelet count \<100 x 106/μL~* hematocrit \< 25%~* liver disease (bilirubin \> 2 mg/dl)~* active bleeding or bleeding diathesis~* gastrointestinal bleeding within the last 6 months~* hemodynamic instability~* acute coronary or cerebrovascular event within 3 months~* malignancy~* concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory drug~* recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- clopidogrel 75 mg/day (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
- clopidogrel 150 mg/day (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
- adjunctive cilostazol (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; \[group 3, 20 patients\]) for 14 days.
- 75mg clopidogrel (Type: ACTIVE_COMPARATOR): control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Children male or female aged 6-11 years (inclusive)~2. Parents or guardians gave written informed consent prior to any trial related procedure and child gave assent~3. Able to communicate well with the Investigator, understanding the protocol requirements and restrictions, and willing to comply with the requirements of the entire trial~4. Subjects should be able to hold 2 milliliter (mL) of any appropriate juice in their mouth for 10 seconds without swallowing it and to keep a candy in the mouth for 20 seconds without swallowing it~5. Children who are able to properly assess and differentiate flavours of different soft drinks~6. Children who are able to use a hedonic scale (children were trained before the study)~Exclusion criteria:~1. Unlikely to comply with the protocol requirements, instructions and trial-related restrictions, example: uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial~2. Children with any condition or dietary habit known to interfere with the sense of smell and taste, ingestion of any medication (except paracetamol)~3. Children with significant illness in the previous 2 weeks~4. Any surgical or medical condition, or any significant disease that in the opinion of the investigator, constitutes a risk or a contraindication for the participation of the subject in the study that could interfere with the study objectives, conduct or evaluation~5. Children who have participated in any clinical investigation within the previous 4 weeks

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- Period 1 and 2 (Type: EXPERIMENTAL): A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
- Period 3, 4 and 5 (Type: EXPERIMENTAL): C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic Knee OA, Kellgren and Lawrence grade I, II, III on plain Rx films.~* Chondromalacia patella grade I-III on knee MRI. With or without meniscal tear.~* Stable knee and normal clinical exam of involved extremity~* Written informed consent for patients.~Exclusion Criteria:~* Bilateral symptomatic knee OA~* Local or systemic infection.~* Active neoplasia or immunosuppressive state~* Pregnancy or Breastfeeding~* Body Mass Index ≥ 30~* Presence of Pacemaker or Lower extremity metal implant~* Anticoagulant treatment other than aspirin.~* Recent use of oral (previous month) or intra-articular (previous 3 months) corticosteroids~* Concomitant inflammatory joint disease (cristal, connective tissue disease)~* Valgus (\>10o) or Varus (\>5o) deformity of involved extremity~* Condilar or Tibial plateau Generalized Bone Marrow edema on MRI~* Significant symptomatic hip or spine disease~* Significant abnormality in baseline lab tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical-cord mesenchymal stromal cells (Type: EXPERIMENTAL): Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months
- Hyaluronic Acid (HA) (Type: ACTIVE_COMPARATOR): Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years, male or female~* DSM-IV criteria for schizophrenia~* Clozapine treatment~* At least 2 scores on the Nocturnal Hypersalivation Rating Scale (NHRS)~Exclusion Criteria:~* Evidence of organic brain damage, mental retardation, alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Moclobemide, (Type: ACTIVE_COMPARATOR): treatment during 2 weeks
- Amisulpride (Type: ACTIVE_COMPARATOR): Comparison

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or post-menopausal females aged 18-80 years.~* Subjects self-identified as black or African-American.~* Diagnosis of hypertension.~* Patients on current anti-hypertensive therapy that does not include beta blockade should have BP \>135/85.~* Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment.~* Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.~Exclusion Criteria:~* Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study~* Inability to return to Emory for follow-up testing~* Age \< 21 or \>80 years~* Premenopausal females with potential for pregnancy~* Acute infection in previous 2 weeks~* On angiotensin antagonists (ACE inhibitors or ARBs)~* History of substance abuse~* Current neoplasm~* Chronic renal failure \[creatinine \> 2.5 mg/dL\] or liver failure (liver enzymes \>2X normal)~* Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months~* Known aortic stenosis, hypertrophic cardiomyopathy.~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol followed by Metoprolol XL (Type: ACTIVE_COMPARATOR): Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
- Metoprolol XL followed by Nebivolol (Type: ACTIVE_COMPARATOR): Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of ASA 1 - 4;~* Subjects above or equal to the age of 18;~* Scheduled for surgical procedures with a general anesthesia requiring neuromuscular relaxation with the use of rocuronium or cisatracurium;~* Scheduled for surgical procedures in supine position;~* Given written informed consent.~Exclusion Criteria:~* Subjects in whom a difficult intubation because of anatomical malformations was expected;~* Subjects known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;~* Subjects known or suspected to have a (family) history of malignant hyperthermia;~* Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Subjects receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;~* Subjects in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Subjects who had already participated in an Org25969 trial;~* Subjects who had participated in another clinical trial (not pre-approved by NV Organon) within 30 days of entering into CT 19.4.310.~* Female subjects who are pregnant:~* Female subjects of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;~* Female subjects who were breast -feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): 2.0 mg/kg Org 25969 (sugammadex)
- Neostigmine (Type: ACTIVE_COMPARATOR): 50 ug/kg neostigmine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete